Osteopore Ltd. · ASX:OSX
Osteopore — Investor Presentation (August 2023)
39 slides from Osteopore's investor presentation, Aug 1, 2023
Slide 1: Investor Presentation August 2023
For personal use only Investor Presentation August 2023 ASX: OSX
Slide 2: Disclaimer
OSTEOPORE.COM Disclaimer This presentation has been prepared by Osteopore Limited Neither the Company, nor its related bodies corporate, of which are outside the control of the Company. For personal use only and its related entities (the “Company”). It does not purport officers, their advisers, agen
Slide 3: Background
OSTEOPORE.COM Background For personal use only Osteopore (ASX:OSX) is a OSX is the first company in the world regenerative medicine company, to develop and commercialise 3D- which specialises in bone and tissue printed bioresorbable implants for regeneration technology that surgery, which can reduce
Slide 4: Mission, Vision, Impact
OSTEOPORE.COM Mission For personal use only Harness our superior technology to become the standard of care globally for natural tissue regeneration. Vision To be the most valuable regenerative medical technology company in the world. Impact Improve clinical outcomes and patient quality-of-life, and
Slide 5: For personal use only
For personal use only https://www.osteopore.com/surgeons/cranioplasty-psi
Slide 6: Regenerative medicine: exciting market opportunity with growth potential
Regenerative medicine OSTEOPORE.COM Exciting market opportunity with growth potential For personal use only High market Links to multiple Reduces Tier 1 valuation technology sectors cost of care market access • In 2022, the global • Links the multi-billion-dollar • With the power to reduce • Japan i
Slide 7: Shaping the future of medicine and science
Regenerative medicine OSTEOPORE.COM Shaping the future of medicine and science For personal use only Fights New era of The future Accelerates chronic healthcare of medicine R&D disease • New era of patient-centred • Regenerative medicine • Promotes the regeneration • In regenerative medicine, health
Slide 8: Revolutionary implants
Revolutionary implants OSTEOPORE.COM Proprietary technology Life changing Multiple applications • Breakthrough 3D printed • Only biomimetic scaffold High Use Implants implants that enable natural that dissolves naturally over time • Multiple off-the-shelf For personal use only bone regeneration impl
Slide 9: Unlocking value-driven healthcare
Unlocking value-driven healthcare OSTEOPORE.COM ‘No-value care’1could be blowing out healthcare For personal use only costs: • In 2022, a study involving 11,897 patients, saw hospital costs increase 1.5-fold 2 • A 20% reduction in hospital re- admissions = 1.6 million hospitalisations = US$15b in sa
Slide 10: Unlocking value-driven healthcare: complication rates
Unlocking value-driven healthcare OSTEOPORE.COM Biomimetic & For personal use only Bone grafts Permanent implants bioresorbable implants 6-19% 25-33% 0.01% Complication Complication Rates Complication Rates Rate 1,2,3 4,5,6 0.01% complication rate, a fraction of other solutions 7 1 Dimitriou et al.,
Slide 11: Breakthrough regenerative technology
Breakthrough regenerative technology OSTEOPORE.COM Transforming medicine with 3D printed bioresorbable implants Regenerative implants For personal use only Printed Distant future organs Biomimetic Stage cells Tissue microstructure propagation regeneration Bioprinted Future tissue Regenerative implan
Slide 12: Evolution of surgical implants
Evolution of surgical implants OSTEOPORE.COM Evolving from covering to bridging, to regenerating bone gaps* Traditional vs. regenerative For personal use only • Today, traditional methods are falling short of patient expectations Meeting patient expectations • Now, with 3D printing and Improving out
Slide 13: Implantation process overview
Implantation process overview OSTEOPORE.COM For personal use only MRM Testing In-vitro incubation Incubated in the lab, then implanted into the patient In-situ Incubation https://doi.org/10.1088/0031-9155/51/3/016 Implanted and incubated in the same location: Week 0 -> Week 4 • One-off procedure • U
Slide 14: How our implants compare
How our implants compare OSTEOPORE.COM Some possible For personal use only consequences Application of Wolff’s Law of not using our Early PSI mineralisation • 120kg patient implants might Bone defect • Initial osseous in-growth • Able to walk without Patient recovery assistance include: • 150mm bone
Slide 15: Case in point: Burr-holes
Case in point: OSTEOPORE.COM Burr-holes 76% of patients complain For personal use only about unsatisfying cosmetic results 1 73.9% of patients had inferiority complexes about • A survey showed a huge discrepancy • In a Korean study, a neurosurgery cosmetic outcomes 2 exists between surgeon and patie
Slide 16: Our products
Our products OSTEOPORE.COM Standard Customised For personal use only Osteoplug is a bioresorbable Osteomesh is a bioresorbable Osteostrip is a durable, Patient Specific Implants (PSI) implant used post- implant used in craniofacial biodegradable used post- Based on CT and MRI-imaging of neurosurgery
Slide 17: Our applications
Our applications OSTEOPORE.COM Aesthetics & Rhinoplasty Patient-centred design Proven solutions in septal extension grafting Aesthetics & For personal use only Rhinoplasty Craniofacial Dental Orbital Surgery Neurosurgery Proven solutions and Proven Orthopaedic developing applications in solutions in
Slide 18: Globally validated technology
Globally validated OSTEOPORE.COM technology For personal use only • Regulatory clearances secured in Tier 1 markets - including FDA (US), CE Mark (Eu.), TGA (Au.), HSA (Sg.) to name a few. • 80,000+ successful cases with superior results over traditional procedures. • Products marketed and sold in 2
Slide 19: Investing in R&D
Investing in R&D OSTEOPORE.COM 3D printed implants Rapid design, manufacturing and delivery • Centre of Excellence – Co-locating design workflow Proprietary technology in proximity to key university and hospital For personal use only ecosystems to increase connectivity with key Strong IP capabilitie
Slide 20: Solutions - Singapore
Solutions- Singapore OSTEOPORE.COM Cranial remodeling Facial and orbital Skull reconstruction floor reconstruction The cranial remodelling of a Skull reconstructed after a For personal use only child with craniosynostosis – a The use of 3D craniotomy – bone removed premature fusion of the skull. bio
Slide 21: Solutions - Global
Solutions- Global OSTEOPORE.COM Accelerating 36cm tibia Bone Regeneration Post-cancer 15cm Half mandible reconstruction tibia reconstruction reconstruction For personal use only The largest-ever reconstruction The post-cancer reconstruction The world’s first of a segmental bone defect. of a 15cm tib
Slide 22: World-first surgeries, life-changing results
World-first surgeries, life-changing results OSTEOPORE.COM Segmental bone Post-cancer bone defect reconstruction Largest-ever construction Post-cancer reconstruction For personal use only of a segmental bone defect 1 of a 15cm tibia 2 • Reconstruction of a • Reconstruction saved leg 36cm tibia from
Slide 23: Our global footprint
Our global footprint OSTEOPORE.COM Europe For personal use only Israel USA Korea China Philippines Japan Vietnam Jordan Singapore Egypt Brazil Australia Current sales markets Near-term target markets 23
Slide 24: Osteopore revenues grow 43% to A$587,226
Osteopore revenues grow 43% to A$587,226 OSTEOPORE.COM Q2 CY23 was a RECORD quarter for Osteopore with a 43% increase in revenues from Q1 CY23 to A$587,226 (S$525,740) 1 Quarterly Sales Revenue in A$’000 For personal use only 700 (S$526) 600 587 EU 2017/745 Effects of COVID-19 (S$461) (MDR) Transiti
Slide 25: Focus on 2024
Focus on 2024 OSTEOPORE.COM Grow revenue • Continue to pursue organic growth opportunities in existing markets For personal use only • Launch products in new markets such as orthopaedic and dental to create additional revenue streams Partnerships • Partner with industry peers to cross-sell products
Slide 26: Core business: Craniofacial
Core business Craniofacial OSTEOPORE.COM Craniotomy Orbital floor reconstruction Product Example Product Example Enables the complete restoration of patients’ Delivers structural support and consistent skull contours in post-craniotomy procedures bone regeneration for orbital floor fractures For per
Slide 27: Key markets: Aesthetics
Key markets Aesthetics OSTEOPORE.COM Septal extension grafting and nasal tip plasty Product Example Provides structural support to achieve long-term and aesthetically pleasing nose For personal use only augmentation outcomes Key highlights Focus on 2024 • 48,000+ cumulative implants since 2017 • Ent
Slide 28: Key markets: Dental/OMF
Key markets Dental/OMF OSTEOPORE.COM Socket preservation Guided bone regeneration Product Example Product Example Implant to reinforce and preserve the dental Supports graft material, delivering a socket following tooth extraction consistent shape to regenerate the bone For personal use only Key hig
Slide 29: Pursuing M&A to boost revenue
Pursuing M&A to OSTEOPORE.COM Direct-to-customer model boost revenue • Pursuing M&A to unlock revenue synergies for Osteopore • Selling full-price products direct-to-customer could increase our margins For personal use only Osteopore has acquired several medical distribution • Higher revenues per pr
Slide 30: Focus on China
Focus on China OSTEOPORE.COM Partnership Sourcing and matching partners to our product segments to commercialise and distribute our products in China For personal use only Regulatory approval Conducting pre-market testing and clinical trials. Submit dossier and obtain National Medical Products Assoc
Slide 31: Focus on China: Paving the way for Chinese market entry
Focus on China OSTEOPORE.COM Paving the way for Chinese market entry Future Dental/Oral For personal use only Craniofacial Aesthetics Orthopaedic Complete Maxillofacial On Track Partnership 1 Regulatory approval Market entry R&D 2 2 1 OSX receives A$10m commitment for commercialisation in China, 25
Slide 32: Blue Sky R&D projects
Blue Sky R&D projects OSTEOPORE.COM Faster bone Cartilage/tendon Veterinary product regeneration regeneration development For personal use only Osteopore is creating We are designing new Osteopore is developing materials to speed up implant scaffolds to surgical applications for bone regeneration re
Slide 33: Turning Blue Sky into a reality
Turning Blue Sky into a reality OSTEOPORE.COM For personal use only A$19m NDCS & A*STAR Accelerate Technologies Livingstone Health A$4m CellHeal University of Chile partnership biologics collaboration collaboration R&D partnership collaboration Osteopore secured the lead role in Osteopore signed two
Slide 34: Board and management
Board and management OSTEOPORE.COM For personal use only Mark Leong Prof. Teoh Swee Hin Daniel Ow Hon. Michael Keenan Executive Chairman Non-Executive Director Non-Executive Director Non-Executive Director ACCA, ISCA, SID B Eng. ( 1 s t Hons); B.Com; CPA (Australia) B. Arts; B. Arts (Hon); M. Phil.
Slide 35: Corporate advisory panel
Corporate advisory panel OSTEOPORE.COM For personal use only Greg Rudd David Yeow Joy Song Tommy Shin Jin Wei Low Director Independent Director CEO & Co-Founder CEO & Co-Founder IP Strategist Glengarry Advisory UOB Kay Hian Holding Ltd. CellHeal Therapeutics Lateral Capital Ventures IPOS Internation
Slide 36: Technical advisory panel
Technical advisory panel OSTEOPORE.COM Neurosurgery surgery Craniofacial surgery Radiology For personal use only A/Prof. Lim Thiam Chye Dr. Tan Bang Wei (Mark) Dr. Rondhir Jithoo MD A/Prof. Yeo Tseng Tsai Dr. Michael Wagels MD Plastic Reconstruction Surgeon Head & Neck Radiology; Neurosurgeon Neuros
Slide 37: Why Osteopore?
Why Osteopore? OSTEOPORE.COM Established pedigree x De-risked profile • Fully validated technology • Osteopore is recognised as a global For personal use only 80K+ • 80K+ successful cases with a growing sales pipeline leader in regenerative medicine • Clear vision to achieve profitability • Leading-
Slide 38: Why Osteopore?
Why Osteopore? OSTEOPORE.COM x Global opportunity Addressable market For personal use only • Sizeable addressable market • Targeting the US$100bn permanent • Potential to be the new standard of care in implant market 1 regenerative medicine globally • Pursuing the US$3.9bn bone graft market with our
Slide 39: Contact details
For personal use only Mark Leong Executive Chairman E: mark_leong@osteopore.com Lim Jing Chief Executive Officer & Chief Technology Officer E: lim_jing@osteopore.com Isaac Stewart Investor & Media Relations E: istewart@canningspurple.com.au